Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A clinical trial shows a possible increased risk of cancer and the FDA is continuing to evaluate the results.
Clinical trials showed a high response rate, with almost 85% of participants experiencing tumor shrinkage with this targeted drug.
In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.
The drug was previously approved for castration-resistant prostate cancer.
New site-agnostic therapies highlight the importance of genetic testing.
Oncologist wins Senate backing by a vote of 72 to 18.
Clinical trials showed that 84% of patients saw tumor shrinkage with this therapy.
A public workshop organized by the FDA and MRA
The plan aims to streamline evaluation of increasingly complex therapies for these life-threatening diseases.
The reorganization is part of modernization plans that were approved in September 2019.
Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.
One reason for late-age (and later stage) diagnosis may be that men and their doctors don’t think of themselves as being at risk.
Implants are extensively tested before approval to demonstrate safety and effectiveness. Still, there are risks associated with all implants
The indication is for people with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with prior chemotherapy regimens.
The approval is based on data from CASSIOPEIA, an open-label, randomized, active-controlled phase 3 study.
The FDA has found a probable cancer-causing contaminant in generic drugs shipped from abroad––most recently, Zantac (ranitidine).
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.